Globus Medical Inc. (GMED) is a leading medical device company which specializes in the design, development, and commercialization of musculoskeletal solutions. The company was founded in 2003 by an accomplished orthopedic expert, David Paul, and has its headquarters located in Audubon, Pennsylvania, United States. The company has a strong presence in the market, serving customers in over 30 countries worldwide within a diverse portfolio of products used to support the spine and trauma surgeries.
Globus Medical Inc. is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol 'GMED'. The company has a well-established reputation for its continual innovation and state-of-the-art technology. Its primary mission is to improve the quality of life for patients suffering from musculoskeletal diseases by providing innovative and high-quality medical solutions.
Globus Medical Inc. boasts a broad product portfolio that includes fusion, minimally invasive, and motion preservation technologies. These products include the Secure-C cervical artificial disc for treating degenerative disc diseases and the CREO® Thoracolumbar System for spinal surgeries. The company also provides disruptive and incremental technology solutions, which are based on patient needs such as the ExcelsiusGPS, a revolutionary robotic navigation platform for spine surgeries.
Furthermore, Globus Medical Inc.'s main distinguishing strength lies within its INNOVEX (Innovation, Excellence, and Acceleration) platform. This is a highly integrated, collaborative platform that allows for rapid development, rigorous validation, and fast commercial launch of new innovative products.
Globus Medical Inc. has a dedicated team of professionals who are committed to research and development, striving to bring forward innovative technologies and breakthrough procedures. As a leading player in the sector, the company has an unwavering commitment to clinical research, education, and medical advancement, which have been evident in the numerous patents and FDA-approved devices to their name.
Interestingly, in its zeal to further expand its offerings, Globus Medical Inc. has supplemented its growth strategy through strategic acquisitions and partnerships. The company has acquired several businesses, including the trauma division of Alphatec Spine and Swiss-based robotic developer, KB Medical.
No doubt, Globus Medical’s commitment to research and development, exceptional product portfolio, global reach, and sound business strategies have earned it a notable position in the medical device sector. In the future, the company aims to continue this trajectory, ensuring that it remains at the forefront of technological advancements in the medical device industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Globus Medical Inc. Class A (GMED) stock, noting a weak near-term sentiment despite long-term strength. It highlights an exceptional 59.8:1 risk-reward setup targeting a 17.4% gain with minimal risk, and outlines three AI-generated trading strategies for different risk profiles. The analysis includes multi-timeframe signal data for near, mid, and long-term horizons, advising on entry, target, and stop-loss levels.
Globus Medical (GMED) is considered potentially undervalued despite strong historical returns and a P/E ratio below industry averages, driven by improved adjusted EBITDA margins. The company's fair value is estimated at $103.23 against a last close of $85.67, with growth expected from its robotics, navigation, and minimally invasive procedures, including the ExcelsiusGPS ecosystem and Excelsius XR headset. However, potential challenges include hospital capital spending and successful integration with NuVasive and Nevro.
Globus Medical Director Stephen T. Zarrilli exercised stock options for 25,000 shares of Class A Common Stock on August 18, 2026, at $53.27 per share. On the same day, he sold all 25,000 shares at a weighted average price of $87.0386 per share, resulting in zero direct beneficial ownership of Globus Medical stock after the transactions. The options were granted in January 2020 and were fully vested.
Globus Medical (GMED) has seen positive momentum with a 7.39% 90-day share price return following an earnings beat and higher EPS outlook. Despite a year-to-date dip, its 1-year total shareholder return is 40.41%. A valuation narrative suggests the stock is 23.3% undervalued, with a fair value of $107.42, driven by integration synergies and expected margin expansion from recent acquisitions.
Globus Medical (GMED) stock has seen renewed attention following a 7.84% gain over the last seven days, despite declines over the past 30 and 90 days. While the company's 1-year total shareholder return is positive at 52.33%, investors are debating whether the recent rebound indicates an undervalued stock or if the re-rating is complete. Simply Wall St's analysis suggests Globus Medical is undervalued with a fair value of $107.42, citing innovation in robotics and minimally invasive procedures, but also notes execution risks.
Globus Medical Director David Davidar transferred 2,500 shares of Class A Common Stock on July 27, 2026, as disclosed in a regulatory filing. This non-sale transaction reduced his direct beneficial ownership while his indirect holdings through a family trust remained significant. The disclosure offers insights into insider trading at the orthopedic implant and surgical robotics manufacturer.